Search - tctmd.com

Displaying 241 - 260 of 3032

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for July 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2024

July 31, 2024

FDA Medical Devices Chief Jeff Shuren Announces Retirement

News Daily News

FDA Medical Devices Chief Jeff Shuren Announces Retirement

July 24, 2024

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

FDA to Add New Diversity Requirements for Certain Clinical Studies

News Daily News

FDA to Add New Diversity Requirements for Certain Clinical Studies

July 15, 2024

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

News Daily News

Lower-Dose Edoxaban May Be an Option After Age 80: ENGAGE AF-TIMI 48 Analysis

July 12, 2024

Valvular Heart Disease Has a Diversity Problem

News Features

Valvular Heart Disease Has a Diversity Problem

Yael L. Maxwell

July 12, 2024

Make Way, at Last, for the Third MitraClip RCT in Functional MR: RESHAPE-HF 2

News Daily News

Make Way, at Last, for the Third MitraClip RCT in Functional MR: RESHAPE-HF 2

July 09, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

Device Correction Issued for HeartMate Monitor Due to Potential Pump Stoppage

News Daily News

Device Correction Issued for HeartMate Monitor Due to Potential Pump Stoppage

June 28, 2024

FDA Approves Cordella Remote PA Pressure Monitoring System for HF

News Daily News

FDA Approves Cordella Remote PA Pressure Monitoring System for HF

Yael L. Maxwell

June 24, 2024

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

Another Low-Cal Sugar Substitute Linked to Cardiovascular Risks

News Daily News

Another Low-Cal Sugar Substitute Linked to Cardiovascular Risks

June 12, 2024

T-TEER for Tricuspid Regurgitation Induces Reverse Remodeling, Works in Tricky Anatomies

News Conference News NY Valves 2024

T-TEER for Tricuspid Regurgitation Induces Reverse Remodeling, Works in Tricky Anatomies

June 07, 2024

What’s Next? Managing the Disease and Advanced Training

Presentation NY Valves 2024

What’s Next? Managing the Disease and Advanced Training

Presenter: Charles J. Davidson

June 07, 2024

Why We Need a "Toolbox" Approach for the Tricuspid Valve

Presentation NY Valves 2024

Why We Need a "Toolbox" Approach for the Tricuspid Valve

Presenter: Georg Nickenig

June 07, 2024

Critical Appraisal of the FDA Trials … TRISCEND II (tricuspid TVR) – Can We Balance the Complications?

Presentation NY Valves 2024

Critical Appraisal of the FDA Trials … TRISCEND II (tricuspid TVR) – Can We Balance the Complications?

Presenter: Brian K. Whisenant

June 07, 2024

Critical Appraisal of the FDA Trials … TRILUMINATE (tricuspid-TEER) – Are PROs Enough?

Presentation NY Valves 2024

Critical Appraisal of the FDA Trials … TRILUMINATE (tricuspid-TEER) – Are PROs Enough?

Presenter: Susheel K. Kodali

June 07, 2024

The Compelling Case for Transcatheter Tricuspid Therapies

Presentation NY Valves 2024

The Compelling Case for Transcatheter Tricuspid Therapies

Presenter: Philipp Lurz

June 07, 2024

The ACURATE Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities

Presentation NY Valves 2024

The ACURATE Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities

Presenter: Helge Möllmann

June 07, 2024

The NAVITOR Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities

Presentation NY Valves 2024

The NAVITOR Self-Expanding TAVR Program: Technology Focus and Clinical Trial Priorities

Presenter: Bassem M. Chehab

June 07, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.